Search the Newsreel

Apogee Therapeutics (NASDAQ:APGE) Stock Rating Lowered by BTIG Research

BTIG Research has downgraded Apogee Therapeutics (NASDAQ:APGE) from a "buy" to a "neutral" rating. This follows a broader trend of analysts issuing "Hold" ratings, with the consensus price target at $121.25, despite the company's shares opening near their 52-week high and reporting a quarterly …

Apogee Therapeutics (APGE): Fairmount-linked funds exercise 42,208 options

Fairmount-affiliated entities reported exercising options to acquire 42,208 shares of Apogee Therapeutics (APGE) common stock on August 7, 2026, at strike prices of $17.00 and $43.85 per share. These shares are held indirectly through Fairmount Healthcare Fund II L.P., with Tomas Kiselak and Peter …

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

Investors often weigh high-margin drug developers against massive healthcare service providers when building a portfolio. Choosing between AbbVie (NYSE:ABBV) and CVS Health (NYSE:CVS) requires balancing biotech growth against retail stability. AbbVie focuses on discovering and commercializing advanced therapies, while CVS Health operates an integrated …

Apogee Therapeutics (APGE) details Q2 2026 losses, AbbVie merger plan and $100M BXLS deal

Apogee Therapeutics (NASDAQ:APGE) Issues Earnings Results, Misses Expectations By $1.00 EPS

Apogee Therapeutics (NASDAQ:APGE) reported a quarterly loss of $2.07 per share, missing analyst expectations by $1.00, as the consensus called for a $1.07 loss. Following the announcement, several analysts downgraded the stock or adjusted their price targets. Insiders have sold approximately $22.0 million worth …

Apogee Therapeutics 2Q 2026: Net loss $85.9M, First half loss $160M — 10-Q Summary

Apogee Therapeutics, Inc. reported a consolidated net loss of $85.9M for Q2 2026 and $160M for the first half of 2026, marking an increase from the previous year, as the company has no product sales. Despite the losses, the company highlighted positive Phase 2 …

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

Apogee Therapeutics announced its second quarter 2026 financial results and provided updates on its corporate and pipeline developments. The company reported a pending acquisition by AbbVie for $135.11 per share, totaling approximately $10.9 billion, and positive 16-week Phase 2 APEX Part B results for …

Apogee Therapeutics Inc. $APGE Shares Acquired by Bank of America Corp DE

Bank of America Corp DE increased its stake in Apogee Therapeutics Inc. (NASDAQ:APGE) by 13.5% in the first quarter, now holding 900,871 shares valued at $75.8 million. Despite this institutional interest, company insiders, including CEO Michael Henderson, sold over 180,000 shares totaling approximately $22 …

Apogee Therapeutics (APGE) Earnings Date and Reports 2026 $APGE

Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares

Carl Dambkowski, an insider at Apogee Therapeutics (NASDAQ:APGE), sold 5,500 shares of the company's stock for approximately $737,935. This sale, conducted under a Rule 10b5-1 plan, reduced his ownership by 3.16% to 168,498 shares. The company's stock traded up 0.3% to $134.84, near its …

Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares

Carl Dambkowski, CMO at Apogee Therapeutics, sold 5,500 shares for $737,934 and acquired 4,125 shares via option exercise for $94,297. These transactions occurred under a pre-arranged trading plan, with the stock trading near its 52-week high and appearing overvalued. The company is also in …

Apogee Therapeutics (APGE) CMO trades stock under 10b5-1 plan

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options for 4,125 shares at $22.86 per share and simultaneously sold 5,500 shares at $134.17 per share on August 5, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted in September 2025. …

Sei Investments Co. Grows Stock Holdings in Apogee Therapeutics Inc. $APGE

Sei Investments Co. significantly increased its stake in Apogee Therapeutics Inc. by 158.5% in the first quarter, bringing its total holdings to 42,203 shares valued at approximately $3.55 million. While institutional ownership of APGE is high at 79.04%, company insiders have sold a substantial …

Apogee Therapeutics stock hits all-time high at 134.47 USD

Apogee Therapeutics stock has reached an all-time high of $134.47, reflecting a significant 270% 1-year return and a market cap of $10.08 billion. This surge comes as the company is set to be acquired by AbbVie for $135.11 per share, valuing it at approximately …

Apogee Therapeutics, Inc. (APGE) Stock Price, News, Quote & History

Apogee Therapeutics, Inc. (APGE) is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology indications. The article provides current stock performance, key financial metrics, analyst ratings, and a company overview, highlighting its drug candidates like Zumilokibart (APG777) in clinical trials …

This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now

Key Points AbbVie posted solid second-quarter financial results, led by its two most important products, Skyrizi and Rinvoq. The company's portfolio and pipeline should help maintain steady revenue and earnings over the medium term. AbbVie has increased its payouts for over 50 consecutive years. …

Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout

Baron Capital's Baron Health Care Fund exited its position in Apogee Therapeutics (APGE) after the company announced an agreement to be acquired by AbbVie Inc. for $135.11 per share. The acquisition, representing a 49.5% premium, led to the fund selling its shares. Despite this, …

Why (APGE) Price Action Is Critical for Tactical Trading

This article analyzes Apogee Therapeutics Inc. (NASDAQ: APGE) for tactical trading, indicating a neutral near and mid-term outlook but a positive long-term bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes …

Is Apogee Therapeutics (APGE) Fully Priced, Or Still A Bargain?

Apogee Therapeutics (APGE) has seen significant returns recently, but its valuation checks indicate it is currently expensive, scoring 1 out of 6 on Simply Wall St.'s valuation scale. The company's stock trades at a high price-to-book ratio compared to the biotech industry average, suggesting …

Apogee Therapeutics (APGE) Holds Onto Strong Momentum, Is Its 8x P B Fair?

Apogee Therapeutics (APGE) to Post Quarterly Earnings on Monday

AbbVie Quietly Solved Its Biggest Problem—Now What?

Key Points Interested in AbbVie Inc.? Here are five stocks we like better. AbbVie posted strong Q2 revenue and earnings growth, driven by its Immunology and Neurosciences segments. Analysts maintain a Moderate Buy consensus with a 76% buy-side bias, and institutional buying trends suggest …

Perceptive Advisors LLC Has $129.65 Million Stock Holdings in Apogee Therapeutics Inc. $APGE

Apogee Therapeutics Inc. $APGE Shares Acquired by Bank of New York Mellon Corp

AbbVie Inc. Q2 2026 Earnings Call Summary

AbbVie Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Apogee Therapeutics, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Shareholders of Apogee are set to receive $135.11 in cash per share. KSF is scrutinizing whether this price and the process leading to …

Capgemini SE (CAPMF) (H1 2026) Earnings Call Highlights: Revenue Surges 11. ...

This article first appeared on GuruFocus. Revenue: EUR12,082 million for H1 2026, up 11.3% year-on-year at constant currency. Bookings: EUR12.602 billion in H1, with a book-to-bill ratio of 1.04. Operating Margin: 12.5% in H1, up 10 basis points year-on-year. Normalized Earnings Per Share (EPS): …

Capgemini sees multi-year IT modernisation boom as firms prepare for AI

By Leo Marchandon July 30 (Reuters) - Capgemini Chief Executive Aiman Ezzat said on Thursday that companies hoping to deploy artificial ‌intelligence at scale will first need to modernise decades-old ‌technology systems, creating what he described as a multi-year investment cycle in data, software …

Capgemini: Notre avis sur l’action après la publication des résultats

Capgemini upgrades its 2026 outlook

Capgemini Services SAS Media relations: Victoire Grux Tel.: +33 6 04 52 16 55 victoire.grux@capgemini.com Investor relations: Vincent Biraud Tel.: +33 1 47 54 50 87 vincent.biraud@capgemini.com Capgemini upgrades its 2026 outlook Revenues of €12,082 million in H1 2026, up +8.8% year-on-year Revenue growth …

Apogee Therapeutics, Inc. Revenue Breakdown – BOATS:APGE

This article provides financial information for Apogee Therapeutics, Inc. (APGE). It outlines various financial data including statements, statistics, dividends, earnings, and segments. The content is primarily a data and navigational page from TradingView, focusing on investment tools and market data for APGE.

Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?

Apogee Therapeutics Inc. (APGE) is outperforming its Medical sector peers this year with a 77.9% gain, significantly higher than the sector's 0.8% average return. The stock holds a Zacks Rank #2 (Buy), and its full-year earnings consensus estimate has increased, indicating stronger analyst sentiment. …

APGE|Apogee Therapeutics Inc|Price:134.310|Chg%:+0.030

This article provides a detailed financial overview of Apogee Therapeutics Inc (APGE), presenting its latest market data, earnings information, and key financial statements. It includes quarterly and annual data for EPS, Net Profit, Balance Sheet particulars like assets and liabilities, and Cash Flow metrics. …